Eight Cycles of Escalated-Dose BEACOPP Compared With Four Cycles of Escalated-Dose BEACOPP Followed by Four Cycles of Baseline-Dose BEACOPP With or Without Radiotherapy in Patients With Advanced-Stage Hodgkin's Lymphoma: Final Analysis of the HD12 Trial of the German Hodgkin Study Group
Peter Borchmann(University of Cologne), Andreas Engert(University Hospital Cologne), Andreas Rank(University of Augsburg), Anthony D. Ho(Heidelberg University), Rolf‐Peter Mueller(University of Turin), Stefan W. Krause(Universitätsklinikum Erlangen), Bernd Dörken(Max Delbrück Center), Jana Marková(Johannes Gutenberg University Mainz), Heinz Haverkamp(Johannes Gutenberg University Mainz), Michael Fuchs(Johannes Gutenberg University Mainz), Christoph Huber(Johannes Gutenberg University Mainz), Hans Konrad Mueller‐Hermelink(Johannes Gutenberg University Mainz), Volker Diehl(University of Cologne), Lothar Kanz(University of Freiburg), Christoph Nerl(Universität Hamburg), Ursula Paulus(Johannes Gutenberg University Mainz), Lenka Šmardová(Johannes Gutenberg University Mainz), Richard Greil(Paracelsus Medical University), Hans‐Theodor Eich(Johannes Gutenberg University Mainz), Thomas Cerny(University of Bern)
Cited by 190
Related Papers
Adjuvant Whole-Brain Radiotherapy Versus Observation After Radiosurgery or Surgical Resection of One to Three Cerebral Metastases: Results of the EORTC 22952-26001 Study
|Journal of Clinical Oncology|2010|2k
Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60)
|The Lancet Oncology|2008|1.1k
Replicative Senescence of Mesenchymal Stem Cells: A Continuous and Organized Process
|PLoS ONE|2008|1.1k
Constitutive nuclear factor-kappaB-RelA activation is required for proliferation and survival of Hodgkin's disease tumor cells.
|Journal of Clinical Investigation|1997|765